| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health |
NCT05098028: Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease |
|
|
| Completed | 2a | 44 | Canada, US, RoW | Low Dose Rifaximin ER, Low Dose Rifaximin DER, High Dose Rifaximin ER, High Dose Rifaximin DER, Placebo | Bausch Health Americas, Inc. | Sickle Cell Disease | 09/23 | 09/23 | | |
ACTRN12612001026819: Bacterial translocation and amelioration of liver cell damage in response to treatment with propranolol, with or without rifaximin, in patients with cirrhosis and portal hypertension |
|
|
| Not yet recruiting | 2 | 50 | | | Professor Stephen Riordan, Professor Stephen Riordan | Cirrhosis and portal hypertension | | | | |
| Ongoing | 2 | 150 | Europe | Xifaxan, Precosa, Precosa, Coated tablet, Capsule, Xifaxan, Precosa | Oslo University Hospital, Oslo University Hospital | Heart failure, Adult patients with systolic heart failure who fulfill the inclusion and exclusion criteria will be invited to participate in the study, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04302402: Multi-dimensional Clinical and Pathophysiological Profiles of Patients With Functional Dyspepsia and Effect of Gut Microbiota Manipulation Using Rifaximin for Its Treatment |
|
|
| Not yet recruiting | 2 | 132 | RoW | Rifaximin, Normix, Placebo | Sanjay Gandhi Postgraduate Institute of Medical Sciences, Institute of Advanced Study in Science and Technology | Dyspepsia | 03/21 | 03/23 | | |
NCT04118699: Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial |
|
|
| Active, not recruiting | 2 | 12 | Japan | Rifaximin oral tablet, L-105, Placebo oral tablet | Yokohama City University, ASKA Pharmaceutical Co., Ltd. | Chronic Intestinal Pseudo-obstruction | 11/21 | 01/22 | | |
NCT04043897: Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis |
|
|
| Recruiting | 2 | 10 | US | Rifaximin 550mg | Eugene F Yen, MD | Microscopic Colitis | 12/21 | 12/21 | | |
NCI-2020-00332, NCT04249622: Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer |
|
|
| Active, not recruiting | 2 | 20 | US | Best Practice, standard of care, standard therapy, Questionnaire Administration, Rifaximin, Xifaxan | Mayo Clinic, National Cancer Institute (NCI) | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8 | 12/22 | 12/24 | | |
NCT04254549: Rifaximin in Patients With Diabetic Gastroparesis |
|
|
| Recruiting | 2 | 40 | US | Rifaximin, TD-1473, Placebo | Mayo Clinic | Crohn Disease, Diabetic Gastroparesis | 12/24 | 12/24 | | |
NCT05502913: Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer |
|
|
| Recruiting | 2 | 80 | RoW | Antibiotics, Rifaximin, FMT (Fecal Microbiota Transplantation) | Soroka University Medical Center, Biotax Labs LTD, Israel Cancer Association | Metastatic Lung Cancer | 06/25 | 06/28 | | |
NCT06058572: Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia |
|
|
| Not yet recruiting | 2 | 166 | NA | Rifaximin with allogeneic stem cell transplant, Allogeneic stem cell transplant | Tata Memorial Centre | Acute Leukemia | 10/26 | 10/26 | | |
NCT04557215: Efficacy and Safety of Rifaximin With NAC in IBS-D |
|
|
| Completed | 1/2 | 45 | US | Rifaximin, xifaxan, N-acetylcysteine, NAC, Placebo | Cedars-Sinai Medical Center, Bausch Health Ireland Limited | Irritable Bowel Syndrome With Diarrhea | 08/21 | 10/22 | | |
NCT05453916: Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation |
|
|
| Recruiting | 1/2 | 84 | RoW | Nitazoxanide 500Mg Oral Tablet, Rifaximin 550Mg Tab | Sadat City University | Irritable Bowel Syndrome With Diarrhea | 07/24 | 12/24 | | |
| Active, not recruiting | 1/2 | 60 | Europe | Fecal Microbiota Transfer provided by Human Biome Institute, Pretreatment with rifaximin 3x 400 mg PO for 7 days, Assessment of levodopa/benserazide 100+25 mg tablet absorption before and 90 days after intervention: 20,40, 60, 90, 120, 150, 180 and 240 min since intervention- Area under the curve (AUC), Cmax, Assessment in clinical scales | Medical University of Warsaw, Human Biome Institute S.A. | Parkinson Disease | 10/23 | 12/24 | | |
| Recruiting | 1/2 | 86 | US | Rifaximin, Placebo | University of California, San Francisco, Nova Southeastern University, Gateway Institute for Brain Research | Parkinson Disease | 12/23 | 12/23 | | |
